247 related articles for article (PubMed ID: 21466969)
21. Hepatitis B virus blood screening: impact of nucleic amplification technology testing implementation on identifying hepatitis B surface antigen non-reactive window period and chronic infections.
Iudicone P; Miceli M; Palange M; Agresti A; Gallo A; Isacchi G; Girolami E; Pierelli L; Mannella E
Vox Sang; 2009 May; 96(4):292-7. PubMed ID: 20701733
[TBL] [Abstract][Full Text] [Related]
22. Multicenter performance evaluation of a transcription-mediated amplification assay for screening of human immunodeficiency virus-1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA in blood donations.
Koppelman MH; Assal A; Chudy M; Torres P; de Villaescusa RG; Reesink HW; Lelie PN; Cuypers HT
Transfusion; 2005 Aug; 45(8):1258-66. PubMed ID: 16078910
[TBL] [Abstract][Full Text] [Related]
23. Emerging viruses and transfusion.
Allain JP
Transfus Clin Biol; 2001 Jun; 8(3):220-1. PubMed ID: 11499963
[TBL] [Abstract][Full Text] [Related]
24. Impact of nucleic acid amplification test on screening of blood donors in Northern Pakistan.
Niazi SK; Bhatti FA; Salamat N; Ghani E; Tayyab M
Transfusion; 2015 Jul; 55(7):1803-11. PubMed ID: 25648663
[TBL] [Abstract][Full Text] [Related]
25. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
Nübling CM; Unkelbach U; Chudy M; Seitz R
Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
[TBL] [Abstract][Full Text] [Related]
26. Blood safety and nucleic acid testing in Europe.
Laperche S
Euro Surveill; 2005 Feb; 10(2):3-4. PubMed ID: 15735316
[No Abstract] [Full Text] [Related]
27. Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios.
El Ekiaby M; Moftah F; Goubran H; van Drimmelen H; LaPerche S; Kleinman S; Busch M; Lelie N
Transfusion; 2015 Jun; 55(6):1186-94. PubMed ID: 25766141
[TBL] [Abstract][Full Text] [Related]
28. Enhanced detection of hepatitis B virus in Hong Kong blood donors after introduction of a more sensitive transcription-mediated amplification assay.
Tsoi WC; Lelie N; Lin CK
Transfusion; 2013 Oct; 53(10 Pt 2):2477-88. PubMed ID: 23521050
[TBL] [Abstract][Full Text] [Related]
29. [Screening for viral genomes in blood transfusion].
Coste J
Transfus Clin Biol; 2000 Jun; 7 Suppl 1():11s-17s. PubMed ID: 10919218
[TBL] [Abstract][Full Text] [Related]
30. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.
Al Shaer L; AbdulRahman M; John TJ; AlHashimi A
Transfusion; 2012 Nov; 52(11):2300-9. PubMed ID: 22691239
[TBL] [Abstract][Full Text] [Related]
31. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.
Shang G; Seed CR; Wang F; Nie D; Farrugia A
Transfusion; 2007 Mar; 47(3):529-39. PubMed ID: 17319836
[TBL] [Abstract][Full Text] [Related]
32. [Evolution of residual risk for HIV, HCV and HBV, from 1999 to 2010, in blood donations of the Centro Hospitalar S. João, EPE, Porto, Portugal].
Koch C; Araújo F
Acta Med Port; 2013; 26(4):371-6. PubMed ID: 24016646
[TBL] [Abstract][Full Text] [Related]
33. Reduction of the risk of transfusion-transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5-year review.
Cable R; Lelie N; Bird A
Vox Sang; 2013 Feb; 104(2):93-9. PubMed ID: 22924987
[TBL] [Abstract][Full Text] [Related]
34. The History and Challenges of Blood Donor Screening in China.
Li L; Li KY; Yan K; Ou G; Li W; Wang J; Song N; Tian L; Ji X; Chen Y; Liang X; Liu Z; Wu Y
Transfus Med Rev; 2017 Apr; 31(2):89-93. PubMed ID: 28012709
[TBL] [Abstract][Full Text] [Related]
35. Blood donors screening for blood born viruses in Poland.
Grabarczyk P; Kopacz A; Sulkowska E; Kubicka-Russel D; Mikulska M; Brojer E; Łętowska M
Przegl Epidemiol; 2015; 69(3):473-7, 591-5. PubMed ID: 26519842
[TBL] [Abstract][Full Text] [Related]
36. Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load.
Katsoulidou A; Moschidis Z; Sypsa V; Chini M; Papatheodoridis GV; Tassopoulos NC; Mimidis K; Karafoulidou A; Hatzakis A
Vox Sang; 2007 Jan; 92(1):8-14. PubMed ID: 17181585
[TBL] [Abstract][Full Text] [Related]
37. [Relevance of safety measures to avoid HTLV transmission by transfusion in 2014].
Laperche S; Pillonel J
Transfus Clin Biol; 2014 Nov; 21(4-5):167-72. PubMed ID: 25267203
[TBL] [Abstract][Full Text] [Related]
38. Emerging infectious disease issues in blood safety.
Chamberland ME; Alter HJ; Busch MP; Nemo G; Ricketts M
Emerg Infect Dis; 2001; 7(3 Suppl):552-3. PubMed ID: 11485669
[TBL] [Abstract][Full Text] [Related]
39. Neopterin levels during the early phase of human immunodeficiency virus, hepatitis C virus, or hepatitis B virus infection.
Nübling CM; Chudy M; Volkers P; Löwer J
Transfusion; 2006 Nov; 46(11):1886-91. PubMed ID: 17076842
[TBL] [Abstract][Full Text] [Related]
40. [Safe blood in the absence of viral infections due to HBV, HCV and HIV in serological window period in donors].
Contreras AM; Reta CB; Torres O; Celis A; Domínguez J
Salud Publica Mex; 2011; 53 Suppl 1():S13-8. PubMed ID: 21877067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
